Exosome RNA Exosome RNA Research & Industry News
exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12 exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses.
Read More »Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor Activity
